Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 9, 2006 Stephen D. Simpson	Riding the Hospira Yo-Yo There's a solid foundation on this roller coaster pharmaceutical and drug delivery company. Maybe Hospira's current valuation doesn't make it a "gem," but that's not really within its control.
The Motley Fool November 9, 2006 Brian Lawler	Hospira's Flatlining Sales There's no good news to be found in this medical products supplier's medicine chest. The upcoming fourth quarter isn't going to be any better, either. Investors, take note.
The Motley Fool August 8, 2007 Ryan Fuhrmann	Hospira Looks to Deliver Will a recent acquisition boost drug delivery firm Hospira's growth prospects? The new Mayne Pharma Limited division played a primary role in delivering an impressive 30% reported sales growth.
The Motley Fool November 11, 2004 Brian Gorman	Hospira's Possibilities The medical products and services outfit is not flashy, but it may benefit from long-term trends. Their stock may be worth monitoring.
The Motley Fool November 10, 2005 Stephen D. Simpson	Hospitable Treatment for Hospira Solid margins fuel strong earnings at the hybrid generics - medical distributor. Buying this stock wisely may be the key to good long-term returns.
The Motley Fool March 1, 2007 Brian Lawler	Hospira's Boring Growth The medical products provider announces its fourth quarter financial results and gives guidance for 2007. Investors, take note.
BusinessWeek May 31, 2004 Robert Barker	Hospira Just May Put You In The Pink If the Abbott Laboratories spin-off's first steps hardly seem promising, that's one reason why I see the company as worth much more of the intelligent investor's attention than the long calendar of pending tech and biotech IPOs.
The Motley Fool January 20, 2011 Jeremy Phillips	Time to Sell Hospira? Hospira has failed two of the quick tests that would make it a sell. This is great, but does it mean you should hold your Hospira shares?
The Motley Fool June 2, 2005 Brian Gorman	Hospira's Little Purchase There may be more to Hospira's recent acquisition than meets the eye.
The Motley Fool October 20, 2005 Stephen D. Simpson	Baxter Needs Growth Infusion This is a fine health-care company, but a sluggish top line suggests there are limits to how far it can go. Trading at nearly 20 times forward earnings, it seems like expectations of a growth revival are already in the stock.
The Motley Fool April 20, 2006 Stephen D. Simpson	More Predictable Unpredictability at ICU Hidden beneath all of the volatility is a pretty decent med-tech business. Recent volatility was the kind that investors like. The stock spiked up as earnings exceeded analyst estimates and the business did a fair bit better than management had projected at the end of last quarter.
The Motley Fool November 9, 2005 Stephen D. Simpson	Fishing for Value at Fisher Even with today's earnings-induced jump, there still might be some value here at researcher Fisher Scientific. Investors, take note.
The Motley Fool May 13, 2005 Brian Gorman	Hospira's Hopeful Signs The medical products company's strong quarter belies a less exciting future. Investors should probably take a wait-and-see attitude.
The Motley Fool October 19, 2005 Stephen D. Simpson	ICU, You Look Healthier An incredible third quarter shows what operating leverage can do for this little medical technology company. Investors, take note.
The Motley Fool September 22, 2006 Brian Lawler	Hospira's New Mate Down Under The specialty injectable pharmaceutical announces an acquisition, but the move means adding on a lot more debt. Investors, take note.
The Motley Fool March 1, 2006 Brian Gorman	Hospira's Stumble In spite of an unsightly quarter, good things still are happening at this medical products and services outfit. Investors, take note.
The Motley Fool January 5, 2010 Brian Orelli	A Deal Manufactured by Necessity Genzyme gets some help from a new friend.
The Motley Fool September 24, 2008 Brian Orelli	Hey, You! Stop! The FDA has ordered Baxter and Hospira to stop making their ophthalmic balanced salt solutions within 60 days.
The Motley Fool January 31, 2006 Stephen D. Simpson	Guidance Puts ICU Medical in the Trauma Ward This oft-volatile stock had a strong fourth quarter, but weak guidance. Even with today's steep drop in price, the shares aren't cheap enough to be interesting.
The Motley Fool August 17, 2005 David Meier	The Power of Margins The way you think about margins can give you an investing edge.
The Motley Fool July 11, 2006 Anders Bylund	Audiovox More Bark Than Bite The electronics company is delivering on its strategy only in the narrowest sense. Investors may be better off with some of the larger competitors, which have all shown a better ability to manage pricing and margins.
The Motley Fool December 9, 2009 Brian Orelli	Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon.
The Motley Fool September 30, 2008 Brian Orelli	Cardinal Health Clips Its Wings Does it make sense for the drug wholesaler to spin off its medical equipment business?
The Motley Fool July 19, 2005 Stephen D. Simpson	Peek-a-Boo ICU ICU Medical has taken on quite a bit of risk in the process of remaking the company. It's best to wait for a reasonable valuation before buying shares.
The Motley Fool July 8, 2010 Selena Maranjian	Get 2-for-1 Stock-Price Growth This one-two punch can lead to serious gains. Stocks that offer both earnings growth and P/E growth can help you rack up knockout returns over the long haul.
The Motley Fool March 10, 2008 Brian Orelli	Breakup Weighs Down APP It's going to take awhile for APP Pharmaceuticals to reward investors.
The Motley Fool May 9, 2006 Rich Smith	Foolish Forecast: TOM on the Line TOM Online, one of China's leading Internet portals and wireless service providers, reports its first-quarter 2006 earnings numbers tomorrow.
The Motley Fool September 2, 2009 Brian Orelli	Should You Buy This Spinoff? Cardinal Health kicks its baby out of the nest.
The Motley Fool August 17, 2006	Comparing Companies Evaluate your investment candidates carefully -- here's how to start.
The Motley Fool November 20, 2006 Brian Gorman	Hospira's Bold Move The drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff.
The Motley Fool July 18, 2006 Rich Smith	Foolish Forecast: General Dynamics Forms Ranks The defense contracting powerhouse reports its second-quarter earnings results early tomorrow. Investors, take note.
Chemistry World February 12, 2015 Rebecca Trager	Hospira buyout is a shot in the arm for Pfizer's biosimilars Pfizer said in a statement that its acquisition of Hospira will create 'a leading global sterile injectables business.
The Motley Fool August 4, 2006 Jim Mueller	O'Charley's Mixed on Margins Improvement in restaurant gross margins is offset by worse operating margins and give mixed results to investors.
The Motley Fool June 9, 2005 Richard Gibbons	Buying on Margins Profit margins are one useful tool for finding great stock values.
The Motley Fool August 26, 2008 Brian Orelli	Baxter Ready to Sop Up Additional Revenue The health-care giant licenses a surgical sponge in clinical development.
The Motley Fool April 18, 2008 Brian Orelli	Recalls Can't Beat Baxter In spite of charges for two recalls, Baxter posts a decent quarter.
The Motley Fool February 23, 2004 Brian Gorman	Abbott Cleans Up Its Act Abbott closes the books on its problems with the FDA and clears the way to a spinoff. Abbott finally passed FDA muster with its Illinois diagnostics plant. Its multi-year problem highlights the importance of investors monitoring manufacturing while watching a pharmaceutical company's pipeline. And with its FDA compliance issues behind it, Abbott can look forward to spinning off its Hospital Products Division.
The Motley Fool February 13, 2009 Brian Orelli	The Easy Way to Develop Drugs Merck buys a pipeline of follow-on biologics and a building to produce them.
BusinessWeek January 29, 2007 Michael Arndt	Abbot Labs: Diagnosis: Shrewd Moves Abbott Laboratories has announced that it is selling about two-thirds of its $4 billion diagnostics business to buy more medical products outfits to help boost overall sales and profits by at least 10% a year into the next decade.
The Motley Fool September 12, 2007 Brian Orelli	Fitting Fission at Abraxis BioScience Abraxis BioScience will split itself into a biotech firm and a generic drug business. Both new companies stand to benefit, but will investors?
IndustryWeek September 1, 2006 David Blanchard	Hospira CEO Chris Begley -- Diagnosis: Green and Lean Chris Begely says manufacturers should become more environmentally responsible. What's more, he's doing something about it.
The Motley Fool July 9, 2004 Phil Wohl	Abbott Labs Concocts Strong Q2 The drug maker reports earnings as expected and refines its third-quarter guidance.
The Motley Fool July 26, 2006 Stephen D. Simpson	Aspect Gives Investors Nightmares The med tech company continues to grow, but high volatility is likely to follow.
IndustryWeek June 1, 2007 Traci Purdum	500 Largest U.S. Manufacturers: Manufacturing Giants This group of manufacturing leaders is demonstrating how to stay competitive in a global economy.
The Motley Fool January 18, 2012 Sean Williams	Are These 2 Medical Device Makers Takeover Targets? Could these two medical device makers put themselves up for sale in 2012?